Search Result
Results for "
reducing intraocular pressure
" in MedChemExpress (MCE) Product Catalog:
3
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0588
-
Brinzolamide
Maximum Cited Publications
7 Publications Verification
AL-4862
|
Carbonic Anhydrase
|
Cardiovascular Disease
Others
Neurological Disease
|
|
Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research .
|
-
-
- HY-B0577
-
|
PHXA41
|
Prostaglandin Receptor
|
Cardiovascular Disease
Others
|
|
Latanoprost (PHXA41) is a prostaglandin F2α analogue and can be used for glaucoma research. Latanoprost can effectively pass through cornea and be hydrolyzed by esterase to latanoprost acid. latanoprost acid is an F-prostaglandin (FP) receptor agonist, and can effectively reduce intraocular pressure (IOP) by increasing the outflow of aqueous humor through uvea .
|
-
-
- HY-B0191
-
|
AGN 192024
|
Prostaglandin Receptor
MMP
|
Cardiovascular Disease
Endocrinology
|
|
Bimatoprost is a prostaglandin analog that reduces intraocular pressure by regulating scleral and trabecular outflow. Bimatoprost is used in the study of open-angle glaucoma, ocular hypertension, and other forms of glaucoma. Topical application of bimatoprost induces fat atrophy and causes a deepening of the eyelid sulcus .
|
-
-
- HY-B0553
-
-
-
- HY-B0397
-
|
Diclofenamide
|
Carbonic Anhydrase
|
Neurological Disease
|
|
Dichlorphenamide (Diclofenamide) is an orally active, specific, carbonic anhydrase inhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research .
|
-
-
- HY-12798
-
|
AR-13324
|
Monoamine Transporter
ROCK
|
Cardiovascular Disease
Neurological Disease
|
|
Netarsudil (AR-13324) is a competitive inhibitor of Rho-associated protein kinases (ROCK I and ROCK II) and a reversible inhibitor of the norepinephrine transporter (NET). Netarsudil reduces intraocular pressure by inhibiting ROCK, causing relaxation of trabecular meshwork cells and dilation of episcleral veins, thereby increasing the ease of aqueous humor outflow, while inhibiting NET to reduce aqueous humor production. Netarsudil is mainly used in the study of ocular hypertension and primary open-angle glaucoma .
|
-
-
- HY-12798B
-
|
AR-13324 hydrochloride
|
ROCK
|
Cardiovascular Disease
Neurological Disease
|
|
Netarsudil (AR-13324) hydrochloride is a competitive inhibitor of Rho-associated protein kinases (ROCK I and ROCK II) and a reversible inhibitor of the norepinephrine transporter (NET). Netarsudil hydrochloride reduces intraocular pressure by inhibiting ROCK, causing relaxation of trabecular meshwork cells and dilation of episcleral veins, thereby increasing the ease of aqueous humor outflow, while inhibiting NET to reduce aqueous humor production. Netarsudil hydrochloride is mainly used in the study of ocular hypertension and primary open-angle glaucoma .
|
-
-
- HY-17494
-
|
(S)-L-714,465; MK 950 free base
|
Adrenergic Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .
|
-
-
- HY-12798A
-
|
AR-13324 dimesylate
|
ROCK
|
Cardiovascular Disease
Neurological Disease
|
|
Netarsudil (AR-13324) dimesylate is a competitive inhibitor of Rho-associated protein kinases (ROCK I and ROCK II) and a reversible inhibitor of the norepinephrine transporter (NET). Netarsudil dimesylate reduces intraocular pressure by inhibiting ROCK, causing relaxation of trabecular meshwork cells and dilation of episcleral veins, thereby increasing the ease of aqueous humor outflow, while inhibiting NET to reduce aqueous humor production. Netarsudil dimesylate is mainly used in the study of ocular hypertension and primary open-angle glaucoma .
|
-
-
- HY-16758
-
|
AR-12286
|
ROCK
|
Neurological Disease
|
|
Verosudil (AR-12286) is a ROCK inhibitor. Verosudil has equal inhibitory activity against ROCK1 and ROCK2 (Ki: 2 nM). Verosudil is less selective for PKA, PKCT, MRCKA, and CAM2A (Ki: 69 nM, 9322 nM, 28 nM, 5855 nM, respectively). Verosudil increases trabecular outflow capacity to reduce intraocular pressure. Verosudil is useful in the study of glaucoma and ocular hypertension .
|
-
-
- HY-15195
-
|
Ro 67-0565; SPP-301
|
Endothelin Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Avosentan (Ro 67-0565; SPP-301) is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure .
|
-
-
- HY-128538
-
|
ONO-9054
|
Prostaglandin Receptor
|
Neurological Disease
|
|
Sepetaprost (ONO-9054) is a dual agonist of the prostaglandin E3 receptor and prostaglandin F receptor. Sepetaprost reduces intraocular pressure in animal models. Sepetaprost is applicable for research on ocular hypertension and open-angle glaucoma .
|
-
-
- HY-119468
-
|
|
Dopamine Transporter
|
Neurological Disease
|
|
Medifoxamine is an orally active monoamine reuptake inhibitor and antidepressant. Medifoxamine preferentially inhibits presynaptic dopamine reuptake. Medifoxamine acts as an intraocular pressure-lowering agent to reduce intraocular pressure, and also functions as a miotic agent to decrease pupil diameter. Medifoxamine exhibits characteristic properties of antidepressant compounds, including preventing hypothermia induced by Reserpine (HY-N0480) or Apomorphine (HY-12723), potentiating the toxic effects of Yohimbine (HY-N0127) in mice, and reducing immobility behavior in mice and rats in the "behavioral despair" model. Medifoxamine has no anticholinergic activity. Medifoxamine can be used in research related to depression .
|
-
-
- HY-142849
-
|
|
Carbonic Anhydrase
|
Endocrinology
|
|
Carbonic anhydrase inhibitor 1 (compound 7c) is a carbonic anhydrase II inhibitor. Carbonic anhydrase inhibitor 3 reduces the intraocular pressure in glaucomatous rabbits .
|
-
-
- HY-116161A
-
|
|
Prostaglandin Receptor
|
Metabolic Disease
|
|
17-Phenyl trinor PGF2α isopropyl ester is a FP receptor agonist and intraocular pressure-lowering agent. 17-Phenyl trinor PGF2α isopropyl ester induces iris sphincter contraction, reduces intraocular pressure and pupil diameter, causes no ocular irritation, and only leads to mild conjunctival hyperemia. 17-Phenyl trinor PGF2α isopropyl ester is applicable to relevant research on glaucoma .
|
-
-
- HY-B0588A
-
|
AL-4862 hydrochloride
|
Carbonic Anhydrase
|
Neurological Disease
|
|
Brinzolamide (AL-4862) hydrochloride is a selective carbonic anhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research .
|
-
-
- HY-121166
-
|
(S)-Betaxolol
|
Adrenergic Receptor
|
Others
|
|
Levobetaxolol is a potent and high affinity β-adrenergic antagonist with IC50 values of 33.2, 2970, 709 nM for guinea pig atrial β1, tracheal β2 and rat colonic β3 receptors, respectively. Levobetaxolol reduces IOP (intraocular pressure). Levobetaxolol exhibits a micromolar affinity for L-type Ca21-channels. Levobetaxolol decreases the effects of ischaemia/reperfusion injury in rats. Levobetaxolol has the potential for the research of glaucoma .
|
-
-
- HY-B0553S
-
|
L584601-d6
|
Isotope-Labeled Compounds
Carbonic Anhydrase
|
Inflammation/Immunology
|
|
Methazolamide-d6 is the deuterium labeled Methazolamide. Methazolamide (L584601) is a sulfonamide derivative used as a carbonic anhydrase inhibitor with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders .
|
-
-
- HY-113756
-
|
|
Prostaglandin Receptor
|
Others
|
|
trans-Latanoprost acid is an isomer of Latanoprost acid. trans-Latanoprost acid may have the activity of reducing intraocular pressure. trans-Latanoprost acid is mainly prepared as an analytical standard for impurity detection and quantification .
|
-
-
- HY-142853
-
|
|
Carbonic Anhydrase
|
Endocrinology
|
|
Carbonic anhydrase inhibitor 3 (compound 11g) is a carbonic anhydrase II inhibitor. Carbonic anhydrase inhibitor 3 reduces the intraocular pressure in glaucomatous rabbits .
|
-
-
- HY-121398
-
|
|
Adrenergic Receptor
Endogenous Metabolite
|
Others
|
|
Dipivefrin is a potent adrenergic agonist. Dipivefrin is an adrenergic pro-agent. Dipivefrin can be used for reduce IOP (intraocular pressure) in patients suffering from chronic open angle glaucoma .
|
-
-
- HY-17494A
-
|
(S)-L-714,465 hemihydrate; MK 950 hemihydrate
|
Adrenergic Receptor
|
Infection
Cancer
|
|
Timolol (hemihydrate) is a β-blocker available for both topical and systemic administration. Timolol (hemihydrate) is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension and Timolol (hemihydrate) also has cardioprotective effect .
|
-
-
- HY-101303
-
|
|
Melatonin Receptor
|
Others
|
|
5-MCA-NAT is a melatonin agonist that may target the melatoninMT3 receptor. 5-MCA-NAT can contract the colonic band in a concentration-dependent manner and reduce intraocular pressure (IOP) in glaucomatous monkey eyes, inhibiting the increase in IOP .
|
-
-
- HY-121902
-
|
|
Adrenergic Receptor
|
Others
|
|
Butidrine is a compound with intraocular pressure-lowering activity that is less effective than some other beta-adrenergic receptor blockers in reducing intraocular pressure in rabbit eyes.
|
-
-
- HY-106332A
-
|
MK 417; (S)-MK-927
|
Carbonic Anhydrase
|
Endocrinology
|
|
Sezolamide hydrochloride (MK 417) is a potent topical carbonic anhydrase inhibitor. Sezolamide hydrochloride can be used in studies to reduce intraocular pressure .
|
-
-
- HY-121600
-
|
|
Cannabinoid Receptor
|
|
|
GAT229 is a CB1 positive allosteric modulator (PAM) that effectively reduces intraocular pressure (IOP) in high IOP mouse models and enhances CB1 receptor-mediated IOP-lowering effects. A 0.2% GAT229 solution or 10 mg/kg of GAT229 alone significantly reduces IOP. GAT229 is promising for research related to glaucoma and elevated intraocular pressure .
|
-
-
- HY-106206
-
-
-
- HY-117090
-
|
(rac)-4,5-DHP-AMT
|
5-HT Receptor
|
Others
|
|
(rac)-AL-37350A ((rac)-4,5-DHP-AMT) is a 5-HT2 receptor agonist with intraocular pressure-lowering activity. (rac)-AL-37350A has high affinity and selectivity for the 5-HT2 receptor and effectively reduces intraocular pressure in conscious hypertensive cynomolgus monkeys.
|
-
-
- HY-B0397A
-
|
Diclofenamide disodium
|
Carbonic Anhydrase
|
Neurological Disease
|
|
Dichlorphenamide (Diclofenamide) disodium is an orally active, specific, carbonic anhydrase inhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research .
|
-
-
- HY-W746807
-
|
N-Cyclohexyl-desamethyl bimatoprost; 17-Phenyl trinor prostaglandin F2α cyclohexyl amide
|
Prostaglandin Receptor
|
Endocrinology
|
|
Bimatoprost cyclohexyl amide (N-Cyclohexyl-desamethyl bimatoprost; 17-Phenyl trinor prostaglandin F2α cyclohexyl amide) is an analog of bimatoprost (HY-B0191). Bimatoprost cyclohexyl amide is an agonist of the prostaglandin F2α receptor. Bimatoprost cyclohexyl amide is used in research on reducing intraocular pressure and glaucoma .
|
-
-
- HY-175085
-
|
|
Drug Derivative
|
Endocrinology
|
|
17-Phenyl trinor 8-iso prostaglandin E2 is a prostaglandin analog that reduces intraocular pressure (IOP) in both normal and glaucomatous monkey eyes. 17-Phenyl trinor 8-iso prostaglandin E2 lowers IOP primarily by increasing trabecular outflow facility .
|
-
-
- HY-B1035C
-
|
(R)-Bunolol hydrochloride
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
ent-Levobunolol ((R)-Bunolol) hydrochloride is a competitive β-adrenergic receptor blocker. ent-Levobunolol hydrochloride inhibits the transmission of sympathetic nerve impulses, reduces the production of aqueous humor, and constricts blood vessels in the eye, thereby reducing intraocular pressure. ent-Levobunolol hydrochloride is promising for research of ocular hypertension diseases such as glaucoma .
|
-
-
- HY-B0397R
-
|
Diclofenamide (Standard)
|
Reference Standards
Carbonic Anhydrase
|
Neurological Disease
|
|
Dichlorphenamide (Standard) is the analytical standard of Dichlorphenamide. This product is intended for research and analytical applications. Dichlorphenamide (Diclofenamide) is an orally active, specific, carbonic anhydrase inhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research .
|
-
-
- HY-106512
-
|
|
Prostaglandin Receptor
|
Others
|
|
Cianergoline is a ergoline derivative with the activity of reducing intraocular pressure (IOP). Its primary regulatory mechanism involves the inhibition of sympathetic nervous function, achieved through actions on both prejunctional (DA2) and postjunctional (α1) adrenergic receptors. Cianergoline can be used for research in the field of glaucoma .
|
-
-
- HY-106916
-
|
|
Potassium Channel
Chloride Channel
|
Cardiovascular Disease
Neurological Disease
|
|
Unoprostone, a prostaglandin F2α analog, is a large conductance Ca 2+-activated K + (BK) channels and ClC-2 type chloride channels activator. Unoprostone reduces oxidative stress- and light-induced retinal cell death, and phagocytotic dysfunction. Unoprostone reduces intraocular pressure and can be used for the study of glaucoma, ocular hypertension and retinitis pigmentosa .
|
-
-
- HY-B0588AS
-
|
AL-4862-d5 hydrochloride
|
Carbonic Anhydrase
|
Neurological Disease
|
|
Brinzolamide-d5 (hydrochloride) is the deuterium labeled Brinzolamide hydrochloride . Brinzolamide (AL-4862) hydrochloride is a selective carbonic anhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research .
|
-
-
- HY-148698
-
|
|
VD/VDR
|
Others
|
|
2MD is an orally active vitamin D analog. 2MD stimulates periosteal bone formation and decreases trabecular bone resorption. Thus 2MD restores trabecular and cortical bone mass and strength. 2MD also regulates intraocular pressure (IOP)-relative genes and reduces IOP in non-human primates .
|
-
-
- HY-124243
-
|
17-Phenyl trinor prostaglandin F2α cyclopropyl methyl amide
|
Prostaglandin Receptor
|
Others
|
|
N-Cyclopropyl methyl bimatoprost (17-Phenyl trinor prostaglandin F2α cyclopropyl methyl amide) is an analog of Bimatoprost (HY-12956). N-Cyclopropyl methyl bimatoprost is an agonist for Prostaglandin F2α Receptor (FP receptor). N-Cyclopropyl methyl bimatoprost is potent to reduce the intraocular pressure and attenuate the glaucoma .
|
-
-
- HY-B0588R
-
|
AL-4862 (Standard)
|
Reference Standards
Carbonic Anhydrase
|
Others
Neurological Disease
|
|
Brinzolamide (Standard) is the analytical standard of Brinzolamide. This product is intended for research and analytical applications. Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research .
|
-
-
- HY-B0191R
-
|
AGN 192024 (Standard)
|
Reference Standards
Prostaglandin Receptor
MMP
|
Cardiovascular Disease
Endocrinology
|
|
Bimatoprost (Standard) is the analytical standard of Bimatoprost. This product is intended for research and analytical applications. Bimatoprost is a prostaglandin analog that reduces intraocular pressure by regulating scleral and trabecular outflow. Bimatoprost is used in the study of open-angle glaucoma, ocular hypertension, and other forms of glaucoma. Topical application of bimatoprost induces fat atrophy and causes a deepening of the eyelid sulcus [4] .
|
-
-
- HY-17494B
-
|
(S)-L-714,465 hemimaleate; MK 950 hemimaleate
|
Adrenergic Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Timolol ((S)-L-714,465; MK 950) hemimaleate is a β-blocker available for both topical and systemic administration. Topical Timolol hemimaleate is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol hemimaleate can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .
|
-
-
- HY-17494S1
-
|
|
Isotope-Labeled Compounds
Adrenergic Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Timolol-d9 (maleate) is deuterium labeled Timolol. Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .
|
-
-
- HY-B0553R
-
-
-
- HY-144705
-
|
|
Cannabinoid Receptor
|
Neurological Disease
|
|
GAT564 (Compound 15d) is a potent allosteric modulator of cannabinoid 1 receptor (CB1R) with EC50s of 87 and 320 nM respectively for cAMP and β-arrestin2. GAT564 markedly promotes orthosteric ligand binding to hCB1R. GAT564 is efficacious as a topical agent that significantly reduces intraocular pressure (IOP) in the ocular normotensive murine model of glaucoma .
|
-
-
- HY-16758A
-
|
AR-12286 hydrochloride
|
ROCK
|
Neurological Disease
|
|
Verosudil (AR-12286) hydrochloride is the hydrochloride form of Verosudil (HY-16758). Verosudil hydrochloride is a ROCK inhibitor. Verosudil hydrochloride has equal inhibitory activity against ROCK1 and ROCK2 (Ki: 2 nM). Verosudil hydrochloride is less selective for PKA, PKCT, MRCKA, and CAM2A (Ki: 69 nM, 9322 nM, 28 nM, 5855 nM, respectively). Verosudil hydrochloride increases trabecular outflow capacity to reduce intraocular pressure. Verosudil hydrochloride is useful in the study of glaucoma and ocular hypertension .
|
-
-
- HY-17494R
-
|
(S)-L-714,465 (Standard); MK 950 free base (Standard)
|
Reference Standards
Adrenergic Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Timolol (Standard) is the analytical standard of Timolol. This product is intended for research and analytical applications. Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .
|
-
-
- HY-124219
-
|
17-Phenoxy trinor PGF2α ethyl amide
|
Prostaglandin Receptor
|
Others
|
|
17-Phenoxy trinor prostaglandin F2α ethyl amide (17-Phenoxy trinor PGF2α ethyl amide) is an analog of Bimatoprost (HY-12956). 17-Phenoxy trinor prostaglandin F2α ethyl amide is an agonist for Prostaglandin F2α Receptor (FP receptor). 17-Phenoxy trinor prostaglandin F2α ethyl amide is potent to reduce the intraocular pressure and attenuate the glaucoma .
|
-
-
- HY-15195R
-
|
Ro 67-0565 (Standard); SPP-301 (Standard)
|
Reference Standards
Endothelin Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Avosentan (Standard) is the analytical standard of Avosentan (HY-15195). This product is intended for research and analytical applications. Avosentan is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction, and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure.
|
-
-
- HY-113778
-
|
15-keto-17-phenyl trinor PGF2α
|
Prostaglandin Receptor
|
Endocrinology
|
|
15-keto-17-phenyl trinor Prostaglandin F2α (15-keto-17-phenyl trinor PGF2α) is an F-series prostaglandin (PG) analog. The potential metabolite of 15-keto-17-phenyl trinor Prostaglandin F2α in animals is 15-keto PG. 15-keto PG can slightly reduce the intraocular pressure (1 mm Hg) in normal cynomolgus monkeys when administered at a dose of 1 μg/eye. 15-keto-17-phenyl trinor Prostaglandin F2α is a miotic agent in cats, reducing the pupil diameter by 8 mm at a dose of 5 μg/eye.
|
-
-
- HY-106332
-
|
MK 417 free base; (S)-MK-927 free base
|
Carbonic Anhydrase
|
Neurological Disease
|
|
Sezolamide (MK 417 free base) is a potent topical carbonic anhydrase inhibitor. Sezolamide can be used in studies to reduce intraocular pressure .
|
-
- HY-127012
-
|
|
Endogenous Metabolite
|
Others
|
|
H-0104 dihydrochloride is a ROCK inhibitor with significant intraocular pressure (IOP)-lowering activity. H-0104 dihydrochloride effectively reduces IOP when administered to monkey eyes. There may not be a direct relationship between the Iop-lowering effect of H-0104 dihydrochloride and ROCK inhibition .
|
-
- HY-182635
-
|
|
Adrenergic Receptor
Sodium Channel
Potassium Channel
|
Cardiovascular Disease
Neurological Disease
|
|
ICI 147798 is an orally effective β-adrenoceptor antagonist with a pKB of 9.1 (in guinea pig right atrium) and 8.8 (in guinea pig trachea). ICI 147798 acts as a diuretic and intraocular pressure-lowering agent. ICI 147798 blocks β-adrenoceptors, inhibits isoproterenol-induced tachycardia and vasodepressor responses, exhibits slowly dissociating, insurmountable antagonism against β1-adrenoceptors, and shows surmountable competitive antagonism against β2-adrenoceptors. ICI 147798 induces natriuresis and kaliuresis, inhibits sodium transport, and reduces intraocular pressure .
|
-
- HY-183283
-
-
- HY-182473
-
|
|
Prostaglandin Receptor
|
Neurological Disease
|
|
AL-6556 is a full agonist of the DP receptor and a partial agonist of the EP2 receptor. AL-6556 has an EC50 of 799 nM for bovine DP, a Ki of 3200 nM for human DP, and an EC50 of 1180 nM for human EP2, with selectivity over EP3, FP, IP, TP and 19 non-prostaglandin receptors. AL-6556 stimulates cAMP production via receptor activation and reduces intraocular pressure through aqueous humor inflow and outflow mechanisms. AL-6556 can be used in research related to ocular hypertension and glaucoma .
|
-
- HY-183905
-
|
|
11β-HSD
Glucocorticoid Receptor
Reactive Oxygen Species (ROS)
Keap1-Nrf2
|
Neurological Disease
|
|
KR-67607 is a selective 11β-HSD1 inhibitor, with an IC50 value of 4.8 nM against h11β-HSD1 and 7.1 nM against mouse 11β-HSD1. KR-67607 inhibits stress-induced Glucocorticoid receptor nuclear translocation, reduces cortisol levels, suppresses the expression of ROS and proinflammatory cytokines, and enhances Nrf-2-mediated antioxidant gene transcription. KR-67607 maintains trabecular meshwork structure and reverses elevated intraocular pressure. KR-67607 improves ocular antioxidant activity and mucus secretion, reverses ocular surface damage, and prevents ischemia-reperfusion induced ocular injury. KR-67607 can be used in research related to glaucoma and dry eye disease .
|
-
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0553S
-
|
|
|
Methazolamide-d6 is the deuterium labeled Methazolamide. Methazolamide (L584601) is a sulfonamide derivative used as a carbonic anhydrase inhibitor with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders .
|
-
-
- HY-B0588AS
-
|
|
|
Brinzolamide-d5 (hydrochloride) is the deuterium labeled Brinzolamide hydrochloride . Brinzolamide (AL-4862) hydrochloride is a selective carbonic anhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research .
|
-
-
- HY-17494S1
-
|
|
|
Timolol-d9 (maleate) is deuterium labeled Timolol. Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: